Methods are disclosed for forming bone and/or cartilage in an avian subject. The methods include administering to the avian subject a therapeutically effective amount of a composition comprising avian mesenchymal stem cells and a hydrogel that supports the differentiation of the avian mesenchymal stem cells into cells of an osteogenic and/or condrogenic lineage. In some embodiments, methods are disclosed for repairing a bone defect and preventing infection, such as that associated bone fracture, in an avian subject. The methods include administering locally to the bone defect a composition comprising a therapeutically effective amount of avian mesenchymal stem cells and a hydrogel, such as a methacrylated gelatin hydrogel.
The invention described herein relates to methods of screening for pro-inflammatory genes and anti-inflammatory genes which may be useful for treating an inflammatory disease, disorder, or otherwise abnormal condition, such as an inflammatory lung disease. The identified pro-inflammatory genes and anti-inflammatory genes may be used to produce pharmaceutical compositions for use in treating the inflammatory disease, disorder, or otherwise abnormal condition.
Disclosed are: a novel nucleic acid; a vector capable of expressing the nucleic acid; a method for screening for a substance capable of controlling the nucleic acid; a method for detecting the expression of the nucleic acid or a mutation in the nucleic acid; and a method for diagnosis or treatment of a disease caused by the abnormality in a mesenchymal stem cell, a mast cell or the like or a disease caused by the abnormal proliferation of a cell (e.g., cancer).
An improved microfluidic device and method of using the microfluidic device to measure natural motile response of a living moiety to a chemotactic agent. The invention comprises integrating microfluidic containment trenches within the microfluidic devices for cellular trapping, manipulation and real-time analysis of biological phenomena, including chemotaxis. The invention captures the design methodology for these traps, as well as the fabrication means and the associated external control mechanism that allows rapid, reversible and fully controlled changes in the chemical environment to which trapped cells are exposed.
Defibrotide for use in prophylaxis and/or treatment of Graft versus Host Disease (GVHD) in humans is disclosed, preferably in hematopoietic stem cell transplantation (HSCT), more preferably allogeneic hematopoietic stem cell transplantation. Graft versus Host Disease of the invention (GVHD) can be acute aGVHD and/or chronic cGVHD, preferably acute.